Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases

G. Rahav, E. Zylber-Katz, D. Rachmilewitz, M. Levy

Research output: Contribution to journalArticlepeer-review

Abstract

We examined 122 patients with inflammatory bowel disease treated with salicylazosulfapyridine. Forty-two (34.5%) had adverse effects that led to discontinuation of therapy in 14 (11.5%). In 33 patients the effects appeared to be dose dependent. The plasma sulfapyridine levels in patients exhibiting gastrointestinal side effects were significantly higher than in patients with no adverse effects (41.0 ± 20.3 and 23.8 ± 14.8 μg/ml respectively, P <0.001). Plasma sulfapyridine levels were significantly higher in slow than in fast acetylators (31.5 ± 17.1 vs. 22.2 ± 17.1 μg/ml). Slow acetylators had three times as many side effects as fast acetylators; however this difference was not statistically significant.

Original languageEnglish
Pages (from-to)31-34
Number of pages4
JournalIsrael Journal of Medical Sciences
Volume26
Issue number1
StatePublished - 1990
Externally publishedYes

Keywords

  • Acetylator phenotype
  • sulfapyridine

Fingerprint

Dive into the research topics of 'Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases'. Together they form a unique fingerprint.

Cite this